Skip to content

An E2 Glycoprotein-based Recombinant Subunit Vaccine Confers Protective Immunity Against Classical Swine Fever Virus in Piglets.

Jul 2026 · Microbial Pathogenesis · Vol 219, pp. 108743 · 0 citations · 22 references
Medicine

TL;DR

The successful development of a recombinant E2 subunit vaccine against CSFV represents a strategic advance toward sustainable control and eventual eradication of the disease.

Abstract

CSFV is a highly contagious disease threatening global pig production. Conventional live vaccines protect effectively but prevent serological differentiation between infected and vaccinated animals-undermining surveillance and eradication efforts. Therefore, it is crucial to develop a new generation of safe and effective vaccines. This study targeted the CSFV E2 glycoprotein, rationally optimized its amino acid sequence, expressed the recombinant protein at high yield in CHO cells, and demonstrated its immunogenicity and complete protection against virulent CSFV challenge. The E2 subunit vaccine was safe in piglets, with no inflammation, fever, or mortality during immunization. The E2 subunit vaccine induces high titers of CSFV-specific and neutralizing antibodies, and its immune protection efficacy is no less than that of commercially available vaccines. In the piglet challenge test, no CSFV was detected in oral, nasal, or rectal swabs or peripheral blood from immunized piglets. No CSFV was detected in the spleen, lymph nodes, or tonsils at autopsy. No CSFV-specific lesions were found on histopathology. All immunized piglets survived. These results demonstrate that piglets vaccinated with the E2 subunit vaccine were completely protected against lethal CSFV challenge. The successful development of a recombinant E2 subunit vaccine against CSFV represents a strategic advance toward sustainable control and eventual eradication of the disease.

View source

Similar papers

Open access Sep 2026

Dual-antigen AdV5 vaccines against Crimean-Congo hemorrhagic fever virus induce superior humoral and Th1-biased cellular immunity

Immunization with adenovirus serotype 5 (AdV5) vectors expressing CCHFV antigens elicited potent humoral and cellular immune responses, conferring 100% protection against lethal viral challenge across the majority of evaluated formulations.

A. Hanifehnezhad, S. Oztop, E. Tavukçuoğlu et al. · 1 citation
Open access Sep 2026

Safety and immunogenicity of a malignant catarrhal fever vaccine candidate expressing ovine gammaherpesvirus-2 glycoprotein B in cattle

Background Infection of susceptible livestock species, including domestic cattle and American bison, with ovine gammaherpesvirus-2 (OvHV-2), a gammaherpesvirus in the genus Macavirus, can result in an often-fatal disease known as sheep-associated malignant catarrhal fever (SA-MCF). Prevention of SA-MCF via vaccination...

Daniela D. Moré, N. Taus, Katherine N. Baker et al. · 0 citations
Open access Sep 2026

Effective protection against PRRSV NADC30 by recombinant chimpanzee adenovirus vaccines expressing GP35 or M-GP5 fusion proteins.

Two recombinant chimpanzee adenovirus vaccine candidates were constructed to express the GP35 or M-GP5 fusion proteins of the PRRSV NADC30-like strain, resulting in a potent antigen-specific immune response, including enhanced GP5-specific antibody production, neutralizing activity, and T-cell-mediated immunity.

Chi Liu, Peng Ma, Jian-Lan Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.